5-137870830-C-T
Variant summary
Our verdict is Pathogenic. Variant got 12 ACMG points: 12P and 0B. PS1_ModeratePM5PP5_Very_Strong
The NM_006790.3(MYOT):c.179C>T(p.Ser60Phe) variant causes a missense change. The variant allele was found at a frequency of 0.0000155 in 1,614,066 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★). Another nucleotide change resulting in same amino acid change has been previously reported as Likely pathogenicin UniProt. Another variant affecting the same amino acid position, but resulting in a different missense (i.e. S60C) has been classified as Likely pathogenic.
Frequency
Consequence
NM_006790.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 12 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MYOT | NM_006790.3 | c.179C>T | p.Ser60Phe | missense_variant | 2/10 | ENST00000239926.9 | NP_006781.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MYOT | ENST00000239926.9 | c.179C>T | p.Ser60Phe | missense_variant | 2/10 | 1 | NM_006790.3 | ENSP00000239926.4 |
Frequencies
GnomAD3 genomes AF: 0.0000131 AC: 2AN: 152176Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.0000361 AC: 9AN: 249028Hom.: 0 AF XY: 0.0000371 AC XY: 5AN XY: 134792
GnomAD4 exome AF: 0.0000157 AC: 23AN: 1461890Hom.: 0 Cov.: 31 AF XY: 0.0000179 AC XY: 13AN XY: 727248
GnomAD4 genome AF: 0.0000131 AC: 2AN: 152176Hom.: 0 Cov.: 32 AF XY: 0.0000269 AC XY: 2AN XY: 74336
ClinVar
Submissions by phenotype
Myofibrillar myopathy 3 Pathogenic:6
Pathogenic, no assertion criteria provided | literature only | OMIM | Apr 27, 2004 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 15, 2023 | This sequence change replaces serine, which is neutral and polar, with phenylalanine, which is neutral and non-polar, at codon 60 of the MYOT protein (p.Ser60Phe). This variant is present in population databases (rs121908458, gnomAD 0.007%). This missense change has been observed in individuals with myofibrillar myopathy (PMID: 15111675, 15947064, 16793270, 19225410, 19590214, 21676617, 25208129, 26842778, 27854214). It has also been observed to segregate with disease in related individuals. ClinVar contains an entry for this variant (Variation ID: 5837). An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. Experimental studies have shown that this missense change affects MYOT function (PMID: 21361873). For these reasons, this variant has been classified as Pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Institute of Human Genetics Munich, Klinikum Rechts Der Isar, TU München | Jun 07, 2019 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | MGZ Medical Genetics Center | May 17, 2022 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Feb 28, 2024 | Variant summary: MYOT c.179C>T (p.Ser60Phe) results in a non-conservative amino acid change in the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 3.6e-05 in 249028 control chromosomes. c.179C>T has been reported in the literature in multiple individuals affected with dominant late-onset myofibrillar myopathy (e.g. Rudolf_2016). These data indicate that the variant is very likely to be associated with disease. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. The following publication has been ascertained in the context of this evaluation (PMID: 27854214). ClinVar contains an entry for this variant (Variation ID: 5837). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Pathogenic, criteria provided, single submitter | clinical testing | Revvity Omics, Revvity | Nov 13, 2023 | - - |
not provided Pathogenic:5
Pathogenic, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Oct 06, 2016 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Athena Diagnostics | Jul 28, 2021 | This variant is statistically more frequent in affected individuals than in the general population and/or healthy controls and is therefore consistent with pathogenicity. This variant appears to be associated with disease in at least one family. At least one other missense variant at this codon is considered to be pathogenic or likely pathogenic, suggesting this variant may also cause disease. Computational tools predict that this variant is damaging. - |
Likely pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Mar 17, 2021 | Reported previously as a heterozygous change in an individual with onset of symptoms of myofibrillar myopathy at age 77 (Selcen et al., 2004; Functional studies of MYOT constructs encoding S60F failed to exhibit altered myotube dynamics; however, the authors suggested that other aspects of protein function not tested by their assay may be affected (Wang et al., 2011); Missense variants in this gene are often considered pathogenic (Stenson et al., 2014); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 32528171, 31589614, 32419263, 32647524, 32509353, 32403337, 31407473, 25208129, 31517061, 19590214, 15111675, 22021208, 27854214) - |
Pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Mar 01, 2021 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics Laboratory, Skane University Hospital Lund | Dec 27, 2023 | - - |
MYOT-related disorder Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Jul 27, 2023 | The MYOT c.179C>T variant is predicted to result in the amino acid substitution p.Ser60Phe. This variant has been reported in the heterozygous state in many unrelated individuals with myofibrillar myopathy (Selcen et al. 2004. PubMed ID: 15111675; McNeill et al. 2009. PubMed ID: 19590214; Semmler et al. 2014. PubMed ID: 25208129; Finsterer et al. 2020 PubMed ID: 32509353; Pénisson-Besnier et al. 2006. PubMed ID: 16793270). Additionally, an alternate substitution at this amino acid position (p.Ser60Cys) has been reported as causative in individuals with myofibrillar myopathy (Selcen et al. 2004. PubMed ID: 15111675). This variant is reported in 0.0071% of alleles in individuals of European (Non-Finnish) descent in gnomAD (http://gnomad.broadinstitute.org/variant/5-137206519-C-T). This variant is interpreted as pathogenic. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at